Polyanhydride nanoparticles encapsulating innate sensor agonists activate epithelial and airway cells and reduce Respiratory Syncytial Virus infection in mice
- PMID: 40419069
- DOI: 10.1016/j.actbio.2025.05.061
Polyanhydride nanoparticles encapsulating innate sensor agonists activate epithelial and airway cells and reduce Respiratory Syncytial Virus infection in mice
Abstract
Acute respiratory tract infections (ARTI) are a leading cause of morbidity and mortality in infants worldwide. Considering the emergence of antimicrobial resistance as a global threat, there is increasing interest in immunomodulatory strategies to prevent respiratory infections. Since ARTIs are caused by several pathogens, immunomodulatory strategies aiming to engage innate responses represent a promising strategy to prevent ARTIs. Here, innate-stimulating nanoparticles (NPs) synthesized from combinations of polyanhydride copolymers and pattern recognition receptor (PRR) agonists were developed to increase disease resistance by activating innate mechanisms at the mucosal level. In vitro analysis on human and bovine respiratory epithelial cells showed that innate-sensor agonist-loaded NPs triggered transcription of inflammatory, antiviral, and antimicrobial mediators. Moreover, pre-treatment with NPs reduced human and bovine orthopneumovirus (RSV) infectious titers in vitro. Intranasal administration of PRR-containing polyanhydride NPs to mice led to transient production of cytokines and chemokines in lungs, suggesting immune activation. The immunogenicity and antiviral properties of NPs were dependent on both polyanhydride copolymer chemistry and the innate agonist encapsulated within the NPs. Prophylactic administration of NPs containing either TLR2/1, TLR4, or TLR2/7 agonists resulted in reduced RSV morbidity and viral lung loads. Selected NPs also showed protective effects when administered 14 days before infection. These results indicate that NPs efficiently prime human and bovine respiratory tract epithelial cells and trigger antiviral defenses in vitro and reduce RSV disease in mice. STATEMENT OF SIGNIFICANCE: Our research focuses on the use of polyanhydride nanoparticles (NPs) encapsulating innate sensor agonists to activate epithelial and airway cells. This innovative approach leverages the unique properties of nanotechnology to harness the innate immune system's potential, providing broad resistance against multiple pathogens. We designed a panel of PRR agonist-loaded polyanhydride NPs with varying chemistries and investigated their effectiveness as innate immunomodulators in the respiratory tract. We demonstrate that NPs activate protective innate immune responses in airway epithelial cells and reduce RSV infectious titers in vitro. NP-treated mice showed protection against RSV-induced morbidity and had reduced viral loads. These findings highlight the potential of polyanhydride NPs as a versatile platform for prophylactic intervention against respiratory viruses in both humans and livestock.
Keywords: Innate immunity; Pattern recognition receptors; Polyanhydride nanoparticles; Respiratory syncytial virus.
Copyright © 2025. Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Balaji Narasimhan is a co-founder of ImmunoNanoMed Inc., a start-up business with interests in the development of nano-based vaccines against infectious diseases.
Similar articles
-
Elimination of gut microbiota hinders the therapeutic effect of amentoflavone on respiratory syncytial virus-induced lung inflammation injury by regulating innate immunity.Phytomedicine. 2025 Sep;145:157033. doi: 10.1016/j.phymed.2025.157033. Epub 2025 Jul 8. Phytomedicine. 2025. PMID: 40701130
-
Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.Health Technol Assess. 2011 Jan;15(5):iii-iv, 1-124. doi: 10.3310/hta15050. Health Technol Assess. 2011. PMID: 21281564 Free PMC article.
-
Both chebulagic acid and punicalagin inhibit respiratory syncytial virus entry via multi-targeting glycoprotein and fusion protein.J Virol. 2024 Dec 17;98(12):e0153624. doi: 10.1128/jvi.01536-24. Epub 2024 Nov 7. J Virol. 2024. PMID: 39508604 Free PMC article.
-
NRF2 agonists 4-octyl-itaconate and dimethyl fumarate reduce human and bovine RSV proliferation and RSV disease in a murine model.Immunohorizons. 2025 Aug 25;9(9):vlaf036. doi: 10.1093/immhor/vlaf036. Immunohorizons. 2025. PMID: 40854594
-
Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection.Cochrane Database Syst Rev. 2023 Oct 23;10(10):CD009417. doi: 10.1002/14651858.CD009417.pub3. Cochrane Database Syst Rev. 2023. PMID: 37870128 Free PMC article.
Cited by
-
Biomimetic nanovaccines in cancer therapy: mechanisms, efficacy, and clinical translation.Mater Today Bio. 2025 Jul 18;34:102116. doi: 10.1016/j.mtbio.2025.102116. eCollection 2025 Oct. Mater Today Bio. 2025. PMID: 40791791 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous